Clinical Trial Update: Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant study evaluating camrelizumab with chemotherapy in triple-negative breast cancer; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN